The main objective of this study is to investigate the effectiveness of lofexidine in
reducing withdrawal symptoms among subjects undergoing opiate detoxification. Currently,
lofexidine is the most commonly used non-opiate medication for detoxification from opiates in
the United Kingdom (UK). There is no non-opiate medication approved by the Food and Drug
Administration (FDA) for the same indication in the United States (US). The only medications
currently approved by the FDA for opiate detoxification are methadone and buprenorphine.
These medications, however, have the potential to be abused. Lofexidine, on the other hand,
offers a unique advantage for opiate detoxification because it is not addicting, is easy to
use, and has a favorable safety profile.
Phase:
Phase 3
Details
Lead Sponsor:
US Department of Veterans Affairs VA Office of Research and Development
Collaborators:
National Institute on Drug Abuse (NIDA) US WorldMeds LLC